Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with an advanced solid tumour that has a specific gene change called a KRAS mutation, in one of these cancer types: pancreatic cancer (ductal adenocarcinoma), colorectal cancer, non-small cell lung cancer, platinum-resistant serous ovarian cancer, bile duct cancer (cholangiocarcinoma), or bladder cancer (urothelial)
- People whose cancer has continued to grow or spread after receiving at least one standard treatment
- People whose cancer can be measured on scans, according to a standard set of measurement rules called RECIST v1.1 (confirm with trial site)
- People with a general health and activity level rated as ECOG 0 or 1, meaning someone who is fully active or has only minor limitations in physically demanding activities (confirm with trial site)
Who may not be able to join:
- People who have had an active, serious infection requiring anti-infective treatment within the 28 days before starting the trial
- People with an active heart or blood vessel (cardiovascular) condition
- People who have a second, separate active cancer that is currently being treated with systemic cancer therapy
- People with liver problems or reduced liver function
- People with untreated cancer that has spread to the brain, or with unstable neurological (brain or nervous system) problems
- People with inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)
- People with an active, untreated overactive thyroid (hyperthyroidism)
- People who have had lupus erythematosus (an autoimmune condition) within the past 5 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-438-884-9551
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1: To characterize the safety and tolerability profiles of WEF-001 administered as monotherapy.; Phase 2: To evaluate the antitumour activity following WEF-001 administration as monotherapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.